CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues:
Total revenue	$ 2,766	$ 1,869	$ 5,163	$ 4,397
Costs and expenses:
Cost of revenue	624	1,042	1,433	1,850
Research and development	8,759	25,275	18,604	47,862
General and administrative	4,752	8,317	11,596	17,107
Licensing	1,285	550	2,316	1,611
Revaluation of contingent consideration	200	(1,500)	3,000	(2,300)
Total costs and expenses	15,620	33,684	36,949	66,130
Loss from operations	(12,854)	(31,815)	(31,786)	(61,733)
Other income, net	1,868	2,246	3,859	4,004
Net loss	$ (10,986)	$ (29,569)	$ (27,927)	$ (57,729)
Net loss per share, basic	$ (0.15)	$ (0.42)	$ (0.39)	$ (0.84)
Net loss per share, diluted	$ (0.15)	$ (0.42)	$ (0.39)	$ (0.84)
Weighted average common shares outstanding, basic	71,291,400	70,633,528	71,183,129	68,763,542
Weighted average common shares outstanding, diluted	71,291,400	70,633,528	71,183,129	68,763,542
Other comprehensive loss:
Unrealized loss on marketable securities, net of tax of $0	$ (99)	$ (757)	$ (357)	$ (214)
Total other comprehensive loss	(99)	(757)	(357)	(214)
Comprehensive loss	(11,085)	(30,326)	(28,284)	(57,943)
Contract research
Revenues:
Total revenue	625	875	1,281	1,764
Licensing
Revenues:
Total revenue	$ 2,141	$ 994	$ 3,882	$ 2,633